Click to access the PDF file: Adequacy of follow up duration in TARGIT-A trial of targeted intraoperative radiotherapy for breast cancer
Adequacy of follow up duration in the TARGIT-A trial
In this short paper, we provide a detailed explanation about the follow-up of the TARGIT-A trial[1, 2] and clarify how it is long enough to be relied upon to guide the application of TARGIT using Intrabeam in routine clinical practice in appropriate patients. We have explained this in the correspondence columns of the Lancet (17 May 2014)
It may appear tempting to speculate that years in the future a difference in local recurrence will become apparent and the difference in mortality that we have already seen will go away, but neither our data nor previous trial results support this speculation, which ignores our understanding about the complex natural history of breast cancer and robust literature about the toxic effects of EBRT on other organs such as the heart.
Continuing to ignore the TARGIT-A trial data can potentially put a large proportion of breast cancer patients at a significant disadvantage. Continue reading
TARGIT-A and TARGIT-B trials: Invited talk at the American Brachytherapy Society meeting, Las Vegas, Oct 2013
Here is a recently published viewpoint on screening mammography
Case selection for TARGIT using hormone receptor status:
Three papers were presented at ASTRO in Sepemeber 2013: two posters and one oral presentation.
Some interesting topics in general surgery that I have written about.
TARGIT at the consensus meeting, St Gallen Breast Cancer symposium, March 2011
19 March 2011
At the 12th International St.Gallen Breast Cancer Conference
16-19 March 2011 / St.Gallen, Switzerland,(~4200 delegates) at the Consensus session on the last day of the conference voted in favour of using intraoperative radiotherapy.